KPTI - Karyopharm inks licensing deal for Nexpovio in Europe and other key global territories

Karyopharm Therapeutics (NASDAQ:KPTI) and privately-held Menarini Group have entered into an exclusive licensing agreement whereby Menarini will commercialize Nexpovio (selinexor) for the treatment of oncology indications in Europe, Latin America and other key countries. KPTI shares up 1.4% premarket at $6.45. Under the terms of the agreement, Karyopharm will receive an upfront payment of $75M in 2021 and is eligible to receive up to an additional $202.5M in future milestones, plus tiered double-digit royalties on net sales of Nexpovio in the licensed territories. Nexpovio, which is marketed as Xpovio in U.S., is an oral Selective Inhibitor of Nuclear Export compound.

For further details see:

Karyopharm inks licensing deal for Nexpovio in Europe and other key global territories